ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma

This study is currently recruiting patients.

Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Antitumor antibiotics such as 17-N-allylamino-17-demethoxygeldanamycin may stop the growth of melanoma by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of 17-N-allylamino-17-demethoxygeldanamycin in treating patients who have stage III or stage IV melanoma.

Condition Treatment or Intervention Phase
stage III melanoma
Stage IV Melanoma
Recurrent Melanoma
 Drug: 17-N-allylamino-17-demethoxygeldanamycin
 Procedure: anti-cytokine therapy
 Procedure: antiangiogenesis therapy
 Procedure: biological response modifier therapy
 Procedure: chemotherapy
 Procedure: growth factor antagonist therapy
Phase II

MedlinePlus related topics:  Melanoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Stage III or IV Melanoma

Further Study Details: 

OBJECTIVES:

OUTLINE: This is a multicenter study. Patients are stratified according to presence of BRAF mutation in tumor (yes vs no).

Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-2 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 32-50 patients (16-25 per stratum) will be accrued for this study within 1.5-2.5 years.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

PATIENT CHARACTERISTICS: Age

Performance status

Life expectancy

Hematopoietic

Hepatic

Renal

Cardiovascular

Other

PRIOR CONCURRENT THERAPY: Biologic therapy

Chemotherapy

Endocrine therapy

Radiotherapy

Surgery

Other


Location and Contact Information


Florida
      H. Lee Moffitt Cancer Center and Research Institute, Tampa,  Florida,  33612-9497,  United States; Recruiting
Adil Daud, MD  813-558-1698 

New Jersey
      Cancer Institute of New Jersey at Robert Wood Johnson University Hospital, New Brunswick,  New Jersey,  08903,  United States; Recruiting
James S. Goydos, MD  732-235-7563 

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States; Recruiting
Jedd D. Wolchok, MD  212-639-6570 

      NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York,  New York,  10016,  United States; Recruiting
Iman Osman, MD  212-686-7500    osmani01@popmail.med.nyu.edu 

Study chairs or principal investigators

Paul B. Chapman, MD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000374980; MSKCC-04056; NCI-6480
Record last reviewed:  August 2004
Record first received:  July 8, 2004
ClinicalTrials.gov Identifier:  NCT00087386
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-22
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act